CG Oncology Reports Second Quarter 2025 Financial Results and Provides Business UpdatesGlobeNewsWire • 08/08/25
CG Oncology to Participate in the Goldman Sachs 46th Annual Global Healthcare ConferenceGlobeNewsWire • 06/05/25
CGON Stock Rallies 27% in a Month on Bladder Cancer Study SuccessZacks Investment Research • 05/22/25
CG Oncology Reports First Quarter 2025 Financial Results and Provides Business UpdatesGlobeNewsWire • 05/13/25
CG Oncology, Inc. (CGON) May Report Negative Earnings: Know the Trend Ahead of Q1 ReleaseZacks Investment Research • 05/01/25
CG Oncology, Inc. (CGON) Surges 25.0%: Is This an Indication of Further Gains?Zacks Investment Research • 04/29/25
CG Oncology Announces Best-in-Disease Durability Data in BOND-003 Cohort C and Promising Early Signal in Cohort P for Cretostimogene Grenadenorepvec at the American Urological Association Annual MeetingGlobeNewsWire • 04/26/25
Wall Street Analysts Believe CG Oncology, Inc. (CGON) Could Rally 157.91%: Here's is How to TradeZacks Investment Research • 03/31/25
Cretostimogene Grenadenorepvec Data Continues to Demonstrate Best-in-Class Durability of Response as well as Consistent and Compelling Safety and EfficacyGlobeNewsWire • 03/24/25
Does CG Oncology, Inc. (CGON) Have the Potential to Rally 123.34% as Wall Street Analysts Expect?Zacks Investment Research • 01/16/25
CG Oncology Announces Closing of Public Offering and Full Exercise of Underwriters' Option to Purchase Additional SharesGlobeNewsWire • 12/16/24
Health Rounds: Experimental CG Oncology immunotherapy shows promise in bladder cancerReuters • 12/06/24
SUO-CTC and CG Oncology Announce the First Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship AwardGlobeNewsWire • 12/06/24
Groundbreaking Cretostimogene Grenadenorepvec Monotherapy Data Demonstrates Sustained, Durable Complete Responses in High-Risk BCG-Unresponsive Non-Muscle Invasive Bladder CancerGlobeNewsWire • 12/05/24